HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Clinical trials for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive 'Tumor Seeker' drug enters human testing for multiple cancers
Disease control Recruiting nowThis is a first-in-human study testing a new radioactive drug designed to target and treat advanced solid tumors. The trial will enroll 180 adults with specific advanced cancers that have progressed after standard treatments. Researchers aim to find a safe and effective dose and …
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Radioactive drug trial offers new hope for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new radioactive drug called [177Lu]Lu-NNS309 in adults with advanced pancreatic, lung, breast, or colorectal cancer that has stopped responding to standard treatments. The main goals are to find a safe dose, see how the drug moves through the b…
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC